查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1997463

代谢体学市场：按成分、适应症、应用和最终用户划分－2026-2032年全球市场预测

Metabolomics Market by Component, Indication, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，代谢体学市场价值将达到 33.9 亿美元，到 2026 年将成长至 37.8 亿美元，到 2032 年将达到 73.9 亿美元，复合年增长率为 11.76%。

主要市场统计数据
基准年 2025 33.9亿美元
预计年份：2026年 37.8亿美元
预测年份 2032 73.9亿美元
复合年增长率 (%) 11.76%

随着科学技术的进步，代谢体学正在发展成为一种系统级能力，对生物医学和环境领域的应用产生了革命性的影响。

随着研究人员和行业相关人员对小分子表型及其转化应用的深入探索，代谢体学领域正日益受到关注。分析仪器和计算能力的最新进展使得在复杂的生物基质中进行更全面、更可重复的代谢物分析成为可能。这些进展正在重塑实验设计，加速生物标记的发现，并拓展代谢体学在药物研发、临床研究、环境监测和营养科学等领域的实际应用。因此，各机构正在重新评估自身将高解析度检测平台与强大的生物资讯流程结合的能力。

分析仪器、分离化学和云生物资讯学的进步正在推动代谢体学向以转化医学为重点的协作生态系统发展。

一场变革性的转变正在发生，它正在重新定义代谢体学的实践、资金筹措和商业化方式。在技术水准，质谱灵敏度和分辨率的提高、核磁共振波谱在无损分析中的广泛应用以及新型表面质谱方法的出现，都提高了代谢物检测和鑑定的可靠性。同时，从毛细管电泳到高效液相层析等分离化学技术的改进，正在提升异构体分离能力，降低基质效应，进而提高数据品质和可解释性。

美国不断变化的关税政策促使全球代谢体学企业调整其策略采购结构，制定供应链弹性计划，并重组其合约。

近期源自美国的关税政策对全球代谢体学供应链产生了多方面的影响，显着影响了筹资策略、供应商选择和成本结构。进口分析仪器和关键零件的关税正在改变采购行为，促使实验室延长仪器使用寿命，尽可能优先选择本地供应商，或探索其他采购管道。这些行为变化对服务供应商和仪器製造商产生了后续影响，他们必须调整分销策略和客户支援模式，以维持市场准入和服务连续性。

多层分割揭示了成分选择、适应症优先顺序、应用重点和最终用户需求如何结合起来，从而确定最佳的代谢体学和商业机会。

市场细分洞察阐明了技术选择与最终用户优先事项的交汇点，并驱动技术的应用路径。基于组件，市场可分为生物资讯学工具和服务以及代谢体学仪器。在生物资讯领域，产品和服务种类繁多，从专用服务到独立工具和资料库，应有尽有。而仪器则分为检测技术和分离平台。检测技术包括质谱、核磁共振波谱和表面质谱，而分离平台则包括毛细管电泳、气相层析法、高效液相层析和超高效液相层析。这种以组件为中心的观点凸显了买家通常更专注于整合的工作流程而非单一产品，他们要求检测精确度和与下游资料处理的兼容性。

美洲、欧洲、中东和非洲以及亚太地区的不同区域趋势，导致代谢体学利害关係人在实施路径和伙伴关係策略方面出现分歧。

区域趋势正在影响代谢体学系统中技术应用的速度、伙伴关係模式和投资重点。在美洲，成熟的学术网路和生物技术产业正在推动尖端检测平台的快速普及，为提供专业代谢体学服务的受託研究机构（CRO）创造了强劲的市场。相较之下，欧洲、中东和非洲（EMEA）地区呈现出多元化的格局，领先的研究中心与优先考虑监管协调和跨境合作研究基础设施的市场并存，从而推动了对可互通数据平台和标准化工作流程的需求。在亚太地区，生命科学领域的投资激增、临床研究能力的提升以及国内製造能力的不断发展，都为本地仪器生产和云端生物资讯服务的应用创造了奖励。

竞争优势源自于硬体和软体的整合创新、协作检验模型以及以服务为中心的方法，从而加速转换可用性。

代谢体学领域的企业正透过检测硬体、先进分离化学和整合生物资讯学服务的创新来打造差异化优势，从而实现端到端的工作流程。其策略重点包括缩短结果获取时间、提高代谢物註释的可靠性以及在多中心研究中实现可扩展的资料管理。市场参与企业正投资于模组化平台，这些平台将高解析度检测与灵活的分离选项相结合，使客户能够针对特定适应症（例如肿瘤学和神经病学研究）客製化分析方法。同时，软体供应商正着重强调互通性、标准化报告格式和机器可读的通路註释，以加速转换应用。

透过采用一体化的产品蓝图、区域服务扩展和协作检验框架，我们加速了各种用例的采用，并减少了实施摩擦。

行业领导者应优先考虑制定一套将仪器性能、分析和服务交付相结合的统一策略，以最大限度地提升价值。首先，调整产品蓝图，使检测平台与分离模组和下游生物资讯工具实现内在相容性，可减少客户整合过程中的阻力，并缩短引进週期。其次，投资于标准化的品质框架和可互通的数据导出，有助于促进多中心合作和监管互动，从而提高在临床和环境应用中的可信度。第三，扩展区域服务基础设施和本地化培训项目，可以满足美洲、欧洲、中东、非洲和亚太地区终端用户的需求，同时缓解关税相关的供应挑战和物流延误。

本研究采用严谨的混合方法，结合对关键相关人员的访谈、技术评估和文献整合，为研究结果提供了支持，并检验了其可操作性。

本研究整合了系统性文献回顾、针对性相关人员访谈、技术产品检验以及产业相关案例研究的证据，建构了代谢体学现状的全面整体情况。第一阶段包括对实验室经理、设备专家、生物资讯学经理和采购经理进行结构化访谈，以确定实际限制因素和推广应用驱动因素。第二阶段包括对同行评审文献、监管指南、专利申请和技术白皮书进行精选审查，以检验技术声明并识别新调查方法的发展趋势。

策略重点放在互通性、检验伙伴关係和适应性经营模式上，将决定哪些组织能够从代谢体学能力中获得长期价值。

总而言之，代谢体学正透过先进检测技术、精密的化学分离技术和可扩展的生物资讯学的融合，发展成为支持转化研究、监管互动和环境监测的核心能力。这种成熟正在推动经营模式的演进，这些模式强调整合工作流程、服务交付和区域适应性。供应链的考量，包括关税政策的影响和区域製造趋势，在增加复杂性的同时，也为差异化服务交付和区域伙伴关係创造了机会。总而言之，可重复性、互通性和协作检验预示着未来，各组织将在提供基于代谢体学的洞见方面发挥主导。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章代谢体学市场：依成分划分

  • 生物资讯学工具和服务
    • 生物资讯服务
    • 生物资讯工具和资料库
  • 代谢体学学设备
    • 检测工具
      • 质谱分析
      • 核磁共振波谱
      • 表面质谱法
    • 分离工具
      • 毛细管电泳
      • 气相层析法
      • 高效液相层析
      • 超高效液相层析

第九章：代谢体学市场：依适应症划分

  • 心血管疾病
  • 代谢性疾病
  • 神经系统疾病
  • 肿瘤性疾病

第十章：代谢体学市场：依应用领域划分

  • 生物标记发现
    • 癌症生物标记
    • 神经系统生物标记
  • 药物发现
    • 代谢途径
    • 目标识别
  • 环境科学
    • 农药残留分析
    • 水质分析
  • 营养基因体学
    • 心血管健康
    • 肥胖调查
  • 个人化医疗
    • 基因组研究
    • 治疗监测
  • 毒性测试

第十一章代谢体学市场：依最终用户划分

  • 学术研究机构
  • 合约研究机构
  • 製药和生物技术公司

第十二章代谢体学市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章代谢体学市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章代谢体学市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国代谢体学市场

第十六章：中国代谢体学市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Afekta Technologies Ltd.
  • BASF SE
  • Bio-Rad Laboratories, Inc.
  • Biocrates Life Science AG
  • Bruker Corporation
  • Clinical Microbiomics A/S
  • Danaher Corporation
  • DNA Xperts Private Limited
  • General Metabolics
  • Hitachi High-Tech Corporation
  • Human Metabolome Technologies Inc.
  • JASCO Corporation
  • Kore Technology Limited
  • LECO Corporation
  • Merck KGaA
  • Metabolon, Inc.
  • Shimadzu Corporation
  • Techcomp Europe Ltd
  • Thermo Fisher Scientific Inc.
  • Waters Corporation
Product Code: MRR-50124643847C

The Metabolomics Market was valued at USD 3.39 billion in 2025 and is projected to grow to USD 3.78 billion in 2026, with a CAGR of 11.76%, reaching USD 7.39 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.39 billion
Estimated Year [2026] USD 3.78 billion
Forecast Year [2032] USD 7.39 billion
CAGR (%) 11.76%

An evolving scientific and technological landscape is elevating metabolomics into a systems-level capability with transformative implications for biomedical and environmental applications

The metabolomics landscape is experiencing heightened attention as researchers and commercial stakeholders pursue deeper understanding of small-molecule phenotypes and their translational applications. Over recent years, advances in analytical instrumentation and computational capacity have converged to enable more comprehensive, reproducible metabolite profiling across complex biological matrices. These developments are reshaping experimental design, accelerating biomarker discovery, and expanding the practical footprint of metabolomics within drug development, clinical research, environmental monitoring, and nutritional science. As a result, organizations are recalibrating capabilities to integrate high-resolution detection platforms with robust bioinformatics pipelines.

Concurrently, the field is maturing from a predominantly exploratory discipline toward one that supports regulated decision-making and clinical utility. The growing emphasis on standardization, quality control, and data interoperability has prompted investment in end-to-end workflows that join sample preparation, separation and detection, and downstream informatics. This integration creates opportunities for improved turnaround times, reproducibility, and cross-study comparability. Given this context, stakeholders should view metabolomics not simply as a technical specialty but as a systems-level capability that empowers precision approaches across therapeutic and environmental domains.

Converging advances in analytical instrumentation, separation chemistries, and cloud-enabled bioinformatics are reshaping metabolomics into a translationally focused and collaborative ecosystem

Transformative shifts are underway that are redefining how metabolomics is practiced, funded, and commercialized. At the technology level, improvements in mass spectrometry sensitivity and resolution, broader adoption of nuclear magnetic resonance spectroscopy for non-destructive profiling, and novel surface-based mass analysis approaches are expanding the detectability and confidence of metabolite identification. In parallel, the refinement of separation chemistries-ranging from capillary electrophoresis to ultra performance liquid chromatography-has enhanced the ability to resolve isomeric species and reduce matrix effects, thereby enriching data quality and interpretability.

On the data side, the integration of advanced bioinformatics tools and services with domain-specific databases is enabling scalable annotation and pathway mapping workflows that were previously prohibitive. The rise of modular, cloud-enabled bioinformatics tools and services is fostering collaborative analytics and reproducible pipelines across institutions. Organizationally, academic research institutes, contract research organizations, and pharmaceutical and biotechnology companies are adopting hybrid models that blend in-house expertise with external service partners to accelerate time-to-insight. Taken together, these shifts are creating a more interoperable, translationally oriented ecosystem in which methodological rigor, data transparency, and cross-sector collaboration determine competitive advantage.

Evolving United States tariff measures are prompting strategic procurement adaptations, supply chain resilience planning, and contract restructuring across global metabolomics operations

Recent tariff policies originating from the United States have produced a multifaceted set of effects across global metabolomics supply chains, with notable implications for procurement strategies, vendor selection, and cost structures. Tariffs that affect imported analytical instruments and key components can alter purchasing behavior, prompting laboratories to extend equipment lifecycles, prioritize local vendors where feasible, or seek alternative procurement channels. These behavioral responses have downstream consequences for service providers and instrument manufacturers who must adapt distribution strategies and customer support models to maintain market access and service continuity.

Beyond procurement, tariff-driven shifts influence collaboration patterns. Academic research institutes and contract research organizations that operate cross-border projects may encounter increased administrative overhead and logistical complexity when sourcing specialized consumables or replacement parts. As a consequence, partnerships that emphasize local manufacturing, in-region servicing, and pre-emptive spare-part inventories gain attractiveness. Moreover, regulatory compliance and customs-related delays can impact study timelines, necessitating contingency planning in project design. Collectively, these dynamics underscore the importance of supply chain resilience and proactive contractual terms when conducting metabolomics research in an environment shaped by evolving trade policies.

Layered segmentation reveals how component choices, indication priorities, application focus, and end-user needs jointly determine optimal metabolomics workflows and commercial opportunities

Insight into market segmentation clarifies where technology choices and end-user priorities intersect to drive adoption pathways. Based on component, the landscape divides between bioinformatics tools and services and metabolomic instruments; within bioinformatics, offerings span dedicated services and standalone tools and databases, while instruments separate into detection technologies and separation platforms, with detection including mass spectrometry, nuclear magnetic resonance spectroscopy, and surface-based mass analysis and separation encompassing capillary electrophoresis, gas chromatography, high-performance liquid chromatography, and ultra performance liquid chromatography. This component-oriented view highlights that purchasers often evaluate integrated workflows rather than discrete products, seeking compatibility between detection fidelity and downstream data processing.

Based on indication, the workstreams concentrate on cardiovascular disorders, metabolic disorders, neurological disorders, and oncological disorders, each of which places distinct demands on sensitivity, longitudinal sampling, and biomarker validation strategies. Based on application, efforts cluster around biomarker discovery, drug discovery, environmental science, nutrigenomics, personalized medicine, and toxicology testing, with biomarker discovery further differentiating into cancer and neurological biomarker initiatives and drug discovery emphasizing metabolic pathway elucidation and target identification; environmental science applications prioritize pesticide residue and water quality analysis while nutrigenomics focuses on cardiovascular health and obesity research and personalized medicine addresses genomic studies and therapeutic monitoring. Based on end-user, the primary consumers include academic research institutes, contract research organizations, and pharmaceutical and biotechnology companies, and each user group balances different trade-offs between throughput, regulatory readiness, and cost-efficiency. Understanding these layered segmentations enables targeted solution design that aligns analytical capability with clinical or environmental validation requirements.

Distinct regional dynamics across the Americas, Europe Middle East and Africa, and Asia-Pacific create differentiated adoption pathways and partnership strategies for metabolomics stakeholders

Regional dynamics shape technology adoption rhythms, partnership models, and investment priorities across the metabolomics ecosystem. In the Americas, established academic networks and a mature biotechnology industry foster rapid uptake of cutting-edge detection platforms and a strong market for contract research organizations that provide specialized metabolomics services. In contrast, Europe, Middle East & Africa presents a heterogeneous landscape in which centers of excellence coexist with markets prioritizing regulatory harmonization and cross-border collaborative research infrastructures, driving demand for interoperable data platforms and standardized workflows. In the Asia-Pacific region, high growth in life sciences investment, expanding clinical research capacity, and evolving domestic manufacturing capabilities create incentives for both local instrument production and adoption of cloud-enabled bioinformatics services.

These regional patterns influence vendor strategies for product localization, training, and after-sales support. They also affect the design of clinical studies and environmental monitoring programs, as regional regulatory expectations and sampling infrastructures differ. Consequently, organizations must develop adaptive market entry plans that reflect local end-user preferences, talent availability, and distribution networks while leveraging global partnerships to ensure access to specialized detection technologies and advanced informatics.

Competitive differentiation emerges from integrated hardware and software innovation, collaborative validation models, and service-centric approaches that accelerate translational utility

Companies operating in the metabolomics space are differentiating through innovation in detection hardware, enhanced separation chemistries, and integrated bioinformatics services that facilitate end-to-end workflows. Strategic priorities include reducing time-to-result, improving metabolite annotation confidence, and enabling scalable data management across multi-site studies. Market participants are investing in modular platforms that pair high-resolution detection with flexible separation options, thereby allowing customers to tailor analytical approaches to specific indications such as oncology or neurological research. Simultaneously, software providers are emphasizing interoperability, standardized reporting formats, and machine-readable pathway annotations to accelerate translational use.

Partnership models are evolving to emphasize co-development with academic consortia and clinical networks, which expedites the validation of biomarkers and the alignment of analytical protocols with clinical endpoints. Service providers and instrument developers are also placing greater emphasis on training and on-site support offerings to lower barriers to adoption. From an operational standpoint, organizations that maintain robust global service footprints, resilient supply chains, and configurable finance options for capital equipment are better positioned to support diverse customer segments. These strategic orientations collectively shape competitive dynamics and determine which entities can sustainably scale across research and commercial applications.

Adopt integrated product roadmaps, regional service expansion, and collaborative validation frameworks to accelerate adoption and reduce implementation friction across diverse use cases

Industry leaders should prioritize cohesive strategies that bridge instrument performance with analytics and service delivery to maximize value capture. First, aligning product roadmaps so that detection platforms are inherently compatible with separation modules and downstream bioinformatics tools will reduce integration friction for customers and shorten adoption cycles. Second, investing in standardized quality frameworks and interoperable data exports will facilitate multi-site studies and regulatory interactions, thereby increasing credibility for clinical and environmental applications. Third, expanding regional service infrastructures and localized training programs will address end-user needs in the Americas, Europe Middle East & Africa, and Asia-Pacific while mitigating tariff-related supply challenges and logistical delays.

Additionally, organizations should pursue strategic collaborations with academic centers and contract research organizations to validate use cases across cardiovascular, metabolic, neurological, and oncological indications. Companies will benefit from offering modular commercial models that encompass instrument-as-a-service, consumable subscriptions, and bespoke analytics engagements tailored to biomarker discovery, drug discovery, nutrigenomics, personalized medicine, environmental science, and toxicology testing. Finally, enhancing transparency around data provenance and analytical uncertainty will build trust with clinical partners and regulators and will support broader adoption of metabolomics-derived decision tools.

A rigorous mixed-methods approach combining primary stakeholder interviews, technical assessments, and literature synthesis underpins the findings and validates practical implications

This research synthesizes evidence from systematic literature reviews, targeted stakeholder interviews, technical product assessments, and cross-validation of industry-relevant case studies to construct a robust portrait of the metabolomics landscape. Primary research involved structured interviews with laboratory directors, instrumentation specialists, bioinformatics leads, and procurement managers to capture practical constraints and adoption drivers. Secondary research entailed a curated review of peer-reviewed literature, regulatory guidance, patent filings, and technology white papers to validate technical assertions and identify emerging methodological trends.

Analytical approaches included technology readiness assessments, workflow mapping to identify integration bottlenecks, and qualitative triangulation of vendor claims against independent academic evaluations. Data quality protocols emphasized reproducibility checks, expert validation panels, and iterative synthesis to ensure that conclusions reflect both operational realities and scientific rigor. Where appropriate, confidential supplier disclosures and anonymized project data were used to corroborate service delivery models and supportability claims, with findings distilled into actionable implications for practitioners, investors, and policy stakeholders.

A strategic focus on interoperability, validation partnerships, and adaptive commercial models will determine which organizations capture long-term value from metabolomics capabilities

In summary, metabolomics is transitioning into a core capability that supports translational research, regulatory engagement, and environmental monitoring through the convergence of advanced detection technologies, refined separation chemistries, and scalable bioinformatics. This maturation is accompanied by evolving commercial models that emphasize integrated workflows, service delivery, and regional adaptability. Supply chain considerations, including the effects of tariff policy and regional manufacturing trends, add complexity but also create opportunities for differentiated service offerings and local partnerships. Taken together, these forces point to a future in which reproducibility, interoperability, and collaborative validation will determine which organizations lead in delivering metabolomics-driven insights.

For stakeholders, the imperative is clear: invest in interoperable platforms, prioritize partnerships that accelerate clinical validation, and design commercial models that reduce implementation friction for end-users across academic, contract research, and pharmaceutical and biotechnology settings. By doing so, organizations can harness metabolomics to generate robust biological insights that meaningfully inform research, product development, and regulatory decision-making.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Metabolomics Market, by Component

  • 8.1. Bioinformatics Tools & Services
    • 8.1.1. Bioinformatics Services
    • 8.1.2. Bioinformatics Tools & Databases
  • 8.2. Metabolomic Instruments
    • 8.2.1. Detection Tools
      • 8.2.1.1. Mass Spectrometry
      • 8.2.1.2. Nuclear Magnetic Resonance Spectroscopy
      • 8.2.1.3. Surface-based Mass Analysis
    • 8.2.2. Separation Tools
      • 8.2.2.1. Capillary Electrophoresis
      • 8.2.2.2. Gas Chromatography
      • 8.2.2.3. High-Performance Liquid Chromatography
      • 8.2.2.4. Ultra Performance Liquid Chromatography

9. Metabolomics Market, by Indication

  • 9.1. Cardiovascular Disorders
  • 9.2. Metabolic Disorders
  • 9.3. Neurological Disorders
  • 9.4. Oncological Disorders

10. Metabolomics Market, by Application

  • 10.1. Biomarker Discovery
    • 10.1.1. Cancer Biomarkers
    • 10.1.2. Neurological Biomarkers
  • 10.2. Drug Discovery
    • 10.2.1. Metabolic Pathways
    • 10.2.2. Target Identification
  • 10.3. Environmental Science
    • 10.3.1. Pesticide Residue Analysis
    • 10.3.2. Water Quality Analysis
  • 10.4. Nutrigenomics
    • 10.4.1. Cardiovascular Health
    • 10.4.2. Obesity Research
  • 10.5. Personalized Medicine
    • 10.5.1. Genomic Studies
    • 10.5.2. Therapeutic Monitoring
  • 10.6. Toxicology Testing

11. Metabolomics Market, by End-User

  • 11.1. Academic Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Pharmaceutical & Biotechnology Companies

12. Metabolomics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Metabolomics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Metabolomics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Metabolomics Market

16. China Metabolomics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Afekta Technologies Ltd.
  • 17.6. BASF SE
  • 17.7. Bio-Rad Laboratories, Inc.
  • 17.8. Biocrates Life Science AG
  • 17.9. Bruker Corporation
  • 17.10. Clinical Microbiomics A/S
  • 17.11. Danaher Corporation
  • 17.12. DNA Xperts Private Limited
  • 17.13. General Metabolics
  • 17.14. Hitachi High-Tech Corporation
  • 17.15. Human Metabolome Technologies Inc.
  • 17.16. JASCO Corporation
  • 17.17. Kore Technology Limited
  • 17.18. LECO Corporation
  • 17.19. Merck KGaA
  • 17.20. Metabolon, Inc.
  • 17.21. Shimadzu Corporation
  • 17.22. Techcomp Europe Ltd
  • 17.23. Thermo Fisher Scientific Inc.
  • 17.24. Waters Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL METABOLOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL METABOLOMICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL METABOLOMICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL METABOLOMICS MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL METABOLOMICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL METABOLOMICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL METABOLOMICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL METABOLOMICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL METABOLOMICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL METABOLOMICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES METABOLOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA METABOLOMICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL METABOLOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & DATABASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & DATABASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & DATABASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL METABOLOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL METABOLOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL METABOLOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL METABOLOMICS MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL METABOLOMICS MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL METABOLOMICS MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL METABOLOMICS MARKET SIZE, BY SURFACE-BASED MASS ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL METABOLOMICS MARKET SIZE, BY SURFACE-BASED MASS ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL METABOLOMICS MARKET SIZE, BY SURFACE-BASED MASS ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL METABOLOMICS MARKET SIZE, BY CAPILLARY ELECTROPHORESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL METABOLOMICS MARKET SIZE, BY CAPILLARY ELECTROPHORESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL METABOLOMICS MARKET SIZE, BY CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL METABOLOMICS MARKET SIZE, BY GAS CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL METABOLOMICS MARKET SIZE, BY GAS CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL METABOLOMICS MARKET SIZE, BY GAS CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL METABOLOMICS MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL METABOLOMICS MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL METABOLOMICS MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL METABOLOMICS MARKET SIZE, BY ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL METABOLOMICS MARKET SIZE, BY ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL METABOLOMICS MARKET SIZE, BY ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL METABOLOMICS MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL METABOLOMICS MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL METABOLOMICS MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL METABOLOMICS MARKET SIZE, BY CANCER BIOMARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL METABOLOMICS MARKET SIZE, BY CANCER BIOMARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL METABOLOMICS MARKET SIZE, BY CANCER BIOMARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL BIOMARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL BIOMARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL BIOMARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC PATHWAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC PATHWAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC PATHWAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL METABOLOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL METABOLOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL METABOLOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL METABOLOMICS MARKET SIZE, BY PESTICIDE RESIDUE ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL METABOLOMICS MARKET SIZE, BY PESTICIDE RESIDUE ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL METABOLOMICS MARKET SIZE, BY PESTICIDE RESIDUE ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL METABOLOMICS MARKET SIZE, BY WATER QUALITY ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL METABOLOMICS MARKET SIZE, BY WATER QUALITY ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL METABOLOMICS MARKET SIZE, BY WATER QUALITY ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL METABOLOMICS MARKET SIZE, BY OBESITY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL METABOLOMICS MARKET SIZE, BY OBESITY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL METABOLOMICS MARKET SIZE, BY OBESITY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL METABOLOMICS MARKET SIZE, BY GENOMIC STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL METABOLOMICS MARKET SIZE, BY GENOMIC STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL METABOLOMICS MARKET SIZE, BY GENOMIC STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL METABOLOMICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL METABOLOMICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL METABOLOMICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL METABOLOMICS MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL METABOLOMICS MARKET SIZE, BY TOXICOLOGY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL METABOLOMICS MARKET SIZE, BY TOXICOLOGY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL METABOLOMICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL METABOLOMICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL METABOLOMICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL METABOLOMICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL METABOLOMICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL METABOLOMICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL METABOLOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL METABOLOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL METABOLOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL METABOLOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS METABOLOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL METABOLOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 251. GCC METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. GCC METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 253. GCC METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 254. GCC METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 255. GCC METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 256. GCC METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 257. GCC METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 258. GCC METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. GCC METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 260. GCC METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 261. GCC METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 262. GCC METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 263. GCC METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 264. GCC METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 293. G7 METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 294. G7 METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 295. G7 METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 296. G7 METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 297. G7 METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 298. G7 METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 299. G7 METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 300. G7 METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 301. G7 METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 302. G7 METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 303. G7 METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 304. G7 METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 305. G7 METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 306. G7 METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 307. NATO METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 308. NATO METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 309. NATO METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 310. NATO METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 311. NATO METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 312. NATO METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 313. NATO METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 314. NATO METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 315. NATO METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 316. NATO METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 317. NATO METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 318. NATO METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 319. NATO METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 320. NATO METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 321. GLOBAL METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES METABOLOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED STATES METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED STATES METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED STATES METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 333. UNITED STATES METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 334. UNITED STATES METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 335. UNITED STATES METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 336. CHINA METABOLOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 337. CHINA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 338. CHINA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 339. CHINA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 340. CHINA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 341. CHINA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS,